Transforming growth factor beta (TGF-β) is activated by the CtBP2-p300-AP1 transcriptional complex in chronic renal

Ping Zhou1, Xiaoxiao Wan1, Yan Zou1

  • 1Department of Nephrology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang 330006, Jiangxi, China.

Insights

Transforming growth factor beta (TGF-β) drives chronic kidney disease progression. A novel CtBP2-p300-AP1 complex upregulates TGFB1, revealing a key mechanism in chronic renal failure.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biochemistry

Background:

  • Chronic renal failure (CRF), or chronic kidney disease (CKD), is a progressive decline in kidney function.
  • Transforming growth factor beta (TGF-β) is implicated in CRF pathogenesis, but its upregulation mechanism remains unclear.

Purpose of the Study:

  • To elucidate the molecular mechanism driving TGF-β upregulation in chronic renal failure.
  • To investigate the role of transcription factors and co-regulators in TGFB1 gene expression.

Main Methods:

  • Analysis of renal biopsies from CRF patients.
  • Gene expression analysis, including promoter region identification (AP-1, NF-κB binding sites).
  • Protein-protein interaction studies (mass spectrometry, coimmunoprecipitation), gene knockdown, and chromatin immunoprecipitation assays.

Main Results:

  • Elevated TGF-β levels correlate with CRF severity.
  • AP-1 (c-Jun, c-Fos) subunits, not NF-κB, regulate TGFB1 expression.
  • A CtBP2-p300-AP1 complex binds the TGFB1 promoter, driving gene expression and TGF-β signaling.

Conclusions:

  • The CtBP2-p300-AP1 complex is a key regulator of TGFB1 in CRF.
  • This finding offers a potential therapeutic target for managing chronic kidney disease progression.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.3K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
495
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
289
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K